Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial of HLD-0915 for metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
This ClinicalTrials.gov update describes the ARCTIC study from Duke University, a prospective set of trials investigating liquid biomarkers …
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW). [Phase 2]
Phase 2 ARROW trial comparing I-131-1095 radioligand plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies [Phase 1, Phase 2]
This Phase 1/2 trial assesses a combination of Avelumab, Utomilumab, and anti-OX40 PF-04518600 with radiation therapy in patients with advan…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors [Phase 1]
This Phase 1 trial update reports on the combination of MGC018 and MGD019 in participants with advanced solid tumors, including castration-r…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 study evaluating OP-3136 in advanced or metastatic solid tumors, including ER-positive/HER2-negative breast cancer, non-small cell l…
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Imaging of Solid Tumors Using DLL3 SPECT [EARLY_Phase 1]
Early Phase 1 clinical trial evaluating DLL3 SPECT imaging for solid tumors, including castration-resistant prostate cancer and neuroendocri…
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer [Phase 3]
Phase 3 trial comparing Lutetium-177 PSMA-617 with androgen receptor–directed therapy in progressive metastatic castration-resistant prostat…
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: 177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer [Phase 3]
A Phase 3 trial comparing 177Lu-PSMA-617 with androgen receptor-directed therapy for progressive metastatic castration-resistant prostate ca…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer [Phase 1]
This update reports the completion of a Phase 1 trial evaluating fractionated docetaxel in combination with radium-223 in metastatic castrat…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]
A Phase 1/2 clinical trial for metastatic castration-resistant prostate cancer conducted by Amgen has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway [Phase 2]
This document reports on a completed Phase 2 trial evaluating the efficacy of carboplatin in metastatic prostate cancer with homologous reco…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: 177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer [EARLY_Phase 1]
The study investigates two radiopharmaceuticals, 177Lu-P17-087 and 177Lu-P17-088, in patients with metastatic castration-resistant prostate …
-
CLINICAL_TRIALS trial_result · 2025-10-02Clinical Trial Update: Abemaciclib With or Without Atezolizumab for mCRPC [Phase 2]
This Phase 2 trial evaluates abemaciclib with or without atezolizumab in metastatic castration-resistant prostate cancer, with results poste…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial [Phase 3]
Phase 3 RECIPROCAL trial examines different dosing schedules of Lutetium-177 Lu-PSMA radioligand therapy in advanced prostate cancer; the st…
-
CLINICAL_TRIALS withdrawal · 2025-09-29Clinical Trial Update: Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer [Phase 2]
Phase 2 trial assessing race-related differences in the efficacy of niraparib plus abiraterone acetate and prednisone in homologous recombin…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: 18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies [Phase 2]
Phase 2 study evaluating 18F-fluciclovine PET imaging in metastatic castration-resistant prostate cancer patients treated with life-prolongi…
-
CLINICAL_TRIALS trial_result · 2025-09-22Clinical Trial Update: Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer [Phase 2]
This Phase 2 trial evaluating sequential oral testosterone undecanoate followed by enzalutamide in men with metastatic castration-resistant …
-
CLINICAL_TRIALS other · 2025-09-19Clinical Trial Update: Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer [Phase 2]
A Phase 2 study of Vidutolimod (CMP-001) in combination with nivolumab for metastatic castration-resistant prostate cancer has been suspende…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones [Phase 1]
This clinical trial update describes a Phase 1 study evaluating how Radium-223 distributes in the body of men with bone-metastatic castratio…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Phase III Radium 223 mCRPC-PEACE III [Phase 3]
Phase III Radium-223 mCRPC-PEACE III trial for metastatic castration-resistant prostate cancer is currently listed as active but not recruit…
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) [Phase 2]
Phase 2 clinical trial evaluating Sacituzumab Tirumotecan in combination with Tagitanlimab for aggressive variant and neuroendocrine prostat…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers [Phase 2]
A Phase 2 trial evaluating Zenocutuzumab in patients with molecularly defined cancers, including non-small cell lung cancer with NRG1 fusion…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: The COSMYC Trial (COmbined Suppression of MYC) [Phase 2]
The COSMYC trial (Combined Suppression of MYC) is a Phase 2 study in metastatic castration-resistant prostate cancer that is currently recru…
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets [Phase 1, Phase 2]
This clinical trial update reports that TQB3201 tablets are being evaluated for tolerability in metastatic castration-resistant prostate can…